Twenty-five patients resected for cutaneous melanoma (stage I and stage II), were subjected to a pilot study of post-surgery adjuvant therapy with recombinant interferon-alpha-2a (IFN, 3 MU/sqm im, every other day, 3 times/week, 4 weeks being considered a 'treatment cycle') for 2 years. The treatment was well tolerated with limited fever and flu-like syndrome, easily controlled by paracetamol. Detailed toxicological analysis pointed out that the treatment produced modest and reversible increase of transaminases, significant decline of white blood cells (WBC) and platelets, not reaching however levels requiring dose reduction or treatment suspension. Reduced WBC count was due mainly to polymorphonucleate down regulation, whereas little reduction of lymphocyte, and modest but significant increase of monocytes during the first treatment cycle was observed. These results support the hypothesis that long-term treatment with low-dose IFN is well tolerated and could be applied safely to patients with limited risk of melanoma recurrence or metastasis.
|Number of pages||6|
|Publication status||Published - 1997|
- adjuvant therapy
ASJC Scopus subject areas